Cargando…
Small molecules and targeted therapies in distant metastatic disease
Chemotherapy, biological agents or combinations of both have had little impact on survival of patients with metastatic melanoma. Advances in understanding the genetic changes associated with the development of melanoma resulted in availability of promising new agents that inhibit specific proteins u...
Autores principales: | Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A. M. M., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., Schadendorf, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712592/ https://www.ncbi.nlm.nih.gov/pubmed/19617296 http://dx.doi.org/10.1093/annonc/mdp254 |
Ejemplares similares
-
Immunotherapy of distant metastatic disease
por: Schadendorf, D., et al.
Publicado: (2009) -
Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009) -
Biomarkers in melanoma
por: Gogas, H., et al.
Publicado: (2009) -
Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009) -
Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)